Latest News

September 06th 2011

AmpliPhi Biosciences to Present at Rodman & Renshaw Annual Global Investment Conference in New York

AmpliPhi Biosciences to Present at Rodman & Renshaw Annual Global Investment Conference in New York
SEATTLE & LONDON, Sep 06, 2011 (BUSINESS WIRE)—AmpliPhi Biosciences Corporation (Other OTC: APHB) announced today that Edward Cappabianca, President and Chief Executive Officer, will present a company update at the Rodman & Renshaw Annual Global Investment Conference taking place September 11-13, 2011 at the Waldorf Astoria Hotel in New York, NY.

Mr. Cappabianca will present on Tuesday, September 13, 2011 at 3:40 p.m. Eastern time in Starlight South. Also attending the investment conference will be David Harper, Ph.D., Chief Scientific Officer.

Management will be conducting one-on-one meetings throughout the conference. To schedule a meeting, please contact your Rodman & Renshaw representative or email .(JavaScript must be enabled to view this email address).

A live and archived webcast of the presentation will be available from the Investor Relations section of the AmpliPhi website under “Webcasts & Presentations.”

AmpliPhi Biosciences

AmpliPhi BioSciences Corporation is a biotechnology company dedicated to the development of innovative anti-bacterial solutions to improve human health through the application of its proprietary bacteriophage platform. The Company’s lead product development programs are targeting Gram negative infections that are often resistant to existing antibiotic treatments. For more information, please visit http://www.ampliphibio.com.

This press release contains certain forward-looking statements that involve known and unknown risks, delays, uncertainties and other factors not under the control of the AmpliPhi Biosciences Corporation. AmpliPhi Bioscience’s actual results, performance or achievements may differ materially from those conveyed in such forward-looking statements. The factors that could cause actual results, performance or achievements to differ from the forward-looking statements includethe possibility that the expected benefits from the Company’s acquisition of Biocontrol Ltd. will not be realized, or will not be realized within the anticipated time period; the risk that the combined businesses will not be integrated successfully; the risk that the Company’s current financial resources and future financial resources will be insufficient to enable the Company to fund continuing operations; and the risk that the Company and its licensee’s product development efforts will be unsuccessful. The Company is not subject to the reporting obligations of the Securities and Exchange Act of 1934 and, accordingly, is not required to file current or periodic reports with the Securities and Exchange Commission.

SOURCE: AmpliPhi Biosciences Corporation

Rathbun Communications
Julie Rathbun, 206-769-9219
.(JavaScript must be enabled to view this email address)